FAQ

Solitomab

Known as: Anti-EpCAM BiTE 
A recombinant bispecific monoclonal antibody directed against both CD3 and epithelial cell adhesion molecule (EpCAM) with potential immunomodulating… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2008-2015
012320082015

Related topics

Related topics

2 relations

Broader (1)

Antibodies, Bispecific

Narrower (1)

MT110

Related mentions per year

Related mentions per year

1983-2018
19801990200020102020
Solitomab
Antibodies, Bispecific
MT110

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro.
BACKGROUND Uterine serous carcinoma is an aggressive form of endometrial cancer that carries an extremely poor prognosis… (More)
Is this relevant?
2015
2015
Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro
BACKGROUND Uterine and ovarian carcinosarcomas (CS) are rare but highly aggressive gynecologic tumors which carry an extremely… (More)
  • table 1
  • figure 2
  • figure 1
  • figure 3
  • figure 4
Is this relevant?
2015
2015
Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy-resistant ovarian cancer cell lines in vitro and fresh tumor cells ex…
BACKGROUND Solitomab is a novel, bispecific, single-chain antibody that targets epithelial cell adhesion molecule (EpCAM) on… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2015
2015
Immunotherapy based on bispecific T-cell engager with hIgG1 Fc sequence as a new therapeutic strategy in multiple myeloma
Bispecific antibodies play an important role in immunotherapy. They have received intense interest from pharmaceutical… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 5
  • figure 7
Is this relevant?
2008
2008
Therapeutic window of MuS110, a single-chain antibody construct bispecific for murine EpCAM and murine CD3.
EpCAM (CD326) is one of the most frequently and highly expressed tumor-associated antigens known and recently has also been found… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?